Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Today's acquisition validates our team's vision and approach

  80% confidence

• This acquisition represents a compelling and strategically aligned opportunity that accelerates Esperion's momentum and advances our long-term Vision 2040

  80% confidence

• The transaction is expected to close in the second quarter of 2026

  80% confidence

• Enbumyst addresses a U.S. market with a potential opportunity exceeding $4 billion

  80% confidence

• The availability of an FDA-approved intranasal diuretic like Enbumyst represents an important therapeutic advance offering potential for more flexible, rapid, and patient-friendly fluid management that can be done at home

  80% confidence

• Enbumyst brings meaningful innovation to millions of patients who continue to struggle with the daily burden of diuretic therapy

  80% confidence

• Edema and congestion remain the most burdensome and persistent symptoms for patients living with heart failure, often driving hospitalizations, impairing quality of life, and complicating day-to-day disease management

  80% confidence

• There are an estimated 6.7 million American adults living with CHF

  80% confidence

• Enbumyst was purpose-built in partnership with the cardiology community to address a clear unmet need

  80% confidence

• By integrating Enbumyst into our proven commercial platform, we will drive sustained double-digit growth, strengthen our leadership in cardiovascular care, and create durable value for all stakeholders

  80% confidence

Cited in these Via News reports

• Private Equity Consortium Pays $12.5 Billion for AES Corporation in Largest US Energy Infrastructure Deal Since 2021 →